Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Prospective Interventional Study of the Tolerability and Efficacy of Oral Harnalidge OCAS (Tamsulosin) 0.4 mg in Patients Who Are Unsatisfied With the Treatment of Tamsulosin 0.2 mg

Next Previous
Trial Profile

An Open-label, Prospective Interventional Study of the Tolerability and Efficacy of Oral Harnalidge OCAS (Tamsulosin) 0.4 mg in Patients Who Are Unsatisfied With the Treatment of Tamsulosin 0.2 mg

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Oct 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tamsulosin (Primary)
  • Indications Benign prostatic hyperplasia; Lower urinary tract symptoms
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma

Most Recent Events

  • 16 Sep 2016 Primary endpoint has been met, (Changes from baseline in total scores of International Prostate Symptom Score (IPSS)), according to the results published.
  • 16 Sep 2016 Efficacy and safety results (n=100) presented at the 46th Annual Meeting of the International Continence Society.
  • 13 Nov 2015 Status changed from recruiting to completed, according to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top